ORIC Pharmaceuticals (ORIC) has already reported preliminary results for three programs in its pipeline, which are: ORIC-944, ORIC-114 and ORIC-533. With respect to ORIC-944 for the treatment of ...

Oric Pharmaceuticals has picked the phase 3 dose for its prostate cancer prospect, barreling into the pivotal program while ...

Anticipated registrational development plans for ORIC-944 and ORIC-114 prioritized to focus on indications with strongest clinical validation and highest unmet need ORIC-944 initiation of first Phase ...

Detailed price information for Oric Pharmaceuticals Inc (ORIC-Q) from The Globe and Mail including charting and trades.

Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership ...

ORIC Pharmaceuticals is walking away from the lead program used to underpin its 2020 IPO after the cancer med fell short in several early-stage trials. ORIC, which stands for overcoming resistance in ...

ORIC-533 continues to demonstrate a best-in-class CD73 inhibitor profile in preclinical analyses. In autologous ex vivo assays using bone marrow aspirates from patients with relapsed refractory ...

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 18, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address ...